In the fall of 2006, a randomized, blinded clinical trial was performed at a commercial feedyard in Nebraska. In a treatment study, a total of 555 high-risk, male beef cattle were treated with either NUFLOR (florfenicol) at 40/mg/kg or Draxxin (tulathromycin) at 2.5 mg/kg after developing respiratory disease. These animals came from a larger population of cattle that were treated with Draxxin at 2.5 mg/kg at the time of initial processing.

Cattle treated with NUFLOR had a net economic advantage of $41.19 over Draxxin-treated cattle. This was due in part to the statistically significant (p<0.05) higher overall and BRD mortality rate in Draxxin-treated animals and the higher treatment cost of Draxxin.

Read the entire white paper (PDF format).